The Michigan Institute for Neurological Disorders (MIND) is proud to announce its role as a Founding Provider Practice in NeuroDiscovery AI—a national alliance of leading neurology groups united to transform neurological care. Through collaboration, innovation, and advanced data analytics, this partnership aims to accelerate treatment breakthroughs and improve patient outcomes nationwide.
This partnership comes at a pivotal time. Neurology research spending is projected to grow 8.3% annually, outpacing other therapeutic areas like oncology. By joining NeuroDiscovery AI, MIND is positioned at the forefront of this momentum—ready to harness the power of real-world data and AI to drive better outcomes for patients.
Through the partnership with NeuroDiscovery AI, MIND joins a national effort to shape the future of neurological care by leveraging:
- Advanced AI tools and analytics for real-time decision-making and performance benchmarking
- Dashboards and imaging tools to support clinical excellence and MIPS reporting
- Opportunities for clinical trials and research in partnership with global pharmaceutical companies
- Collaborative publication support to help translate data into peer-reviewed insights
- Access to next-generation biomarker and imaging research, accelerating the discovery of novel diagnostic and therapeutic targets
As part of this alliance, MIND will continue to support and advance care, research, and innovation for neurological conditions such as migraines, Alzheimer’s disease, Frontotemporal Dementia (FTD), Multiple Sclerosis, and Parkinson’s disease.
This collaboration strengthens MIND’s ability to provide cutting-edge, evidence-based care—and expands our role in shaping the future of neurology through research, technology, and shared expertise.
Learn more at neurodiscovery.ai